Since the presentation of trials such as the Intergroup N9741 study (National Cancer Institute of Canada CO.15) Once a guideline is made available by the PEBC, it undergoes a joint review process in Ontario that evaluates all cancer-related drugs for consideration under the New Drug Funding Program or the Ontario Drug Benefit program, or both. The Committee to Evaluate Drugs (CED), an expert advisory committee to the Ministry of Health and Long-Term Care, conducts the joint review and makes a recommendation regarding the funding of the drug in the province of Ontario 6 .
Given the intrinsic delays in the rigorous PEBC guideline development cycle, the CED has always accepted late drafts of the recommendations to assist in making timely decisions for emerging therapies. The guidelines on colorectal cancer were therefore made available to the CED in 2006.
Complicating the story for oxaliplatin was the absence of a Health Canada Notice of Compliance (NOC). In the context of the incomplete intellectual property protection pertaining in Canada before October 2006, Sanofi-Aventis could not submit its confidential data 7 from an extensive research and development program without running the risk of seeing its oxaliplatin product Eloxatin immediately become genericized. When that situation changed, and data protection provisions were read into law, Sanofi-Aventis could then apply for 8 years of patent protection under the new legislation.
And so, while the rest of the world's regulators approved oxaliplatin (the U.S. Food and Drug Administration's approval for metastatic disease came in 2002, and for stage III colon cancer in 2004 8 ), Health Canada could make oxaliplatin available only through a special access program. Canadians were left with a patchwork of provincial approaches to the coverage of oxaliplatin. British Columbia provided the drug; Quebec gave approval only on a hospital-by-hospital basis. Ontario took the rigid position that, as long as the drug lacked a NOC, it could not be funded. Ontario patients were at the mercy of the self-pay, albeit generously Sanofi-Aventis-sponsored, Special Access Program-a means-tested co-pay model.
On June 15, 2007, oxaliplatin received a NOC for metastatic colorectal cancer, and the CED quickly reviewed the drug. The funding conditions announced (Table I) 
